Developmental Research Program

发展研究计划

• 批准号: 10456964
• 负责人: LARRY W KWAK
• 金额: $ 12.31万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-02 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10456964
• 关键词: Alabama; Award; Basic Science; Cities; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Data; Development; Equipment; Evaluation; Evolution; Extramural Activities; Feedback; Fostering; Fruit; Funding; Goals; Grant; Human Resources; Incidence; Institution; Investigation; Laboratory Study; Lymphoma; Malignant Neoplasms; Minor; Minority; Monitor; Morbidity - disease rate; Patients; Pilot Projects; Population Sciences; Population Study; Positioning Attribute; Prevention; Problem Solving; Program Research Project Grants; Program Reviews; Recommendation; Request for Applications; Research; Research Personnel; Research Project Grants; Review Committee; Scientist; Translating; Translational Research; Universities; Update; Wing; Woman; base; cost; experience; innovation; meetings; member; mortality; programs; success; translational potential

The purpose of the Developmental Research Program (DRP) is to identify and support first-rate, pioneering translational projects in lymphoma that, despite their potential, are not yet mature for full program status. All members of the research community at City of Hope and University of Alabama Birmingham (UAB) are encouraged to consider the opportunity. We have requested $50,000 per year to support this program, and City of Hope and UAB will match these funds annually by $100,000 and $25,000, respectively. At least two researchers per year receive awards, which are granted for up to two years. Funds can be devoted to research supplies and minor equipment, personnel costs, and relevant meeting expenses. Promising investigations may replace SPORE research projects that have either acquired funding as independent R01/P01 projects, or those that have not satisfactorily progressed. Drs. Larry Kwak, Wing (John) Chan, and Ravi Bhatia, longstanding leaders in their field, are the Developmental Program Directors. A request for applications will be advertised and sent to the entire City of Hope and UAB research committees. Proposals from women and minority applicants are encouraged. Proposed projects are reviewed on the basis of scientific merit, likelihood of benefit to lymphoma patients, qualifications of key personnel, and the potential for interaction with the projects and cores of the City of Hope Lymphoma SPORE. Selected projects are fully integrated into the overall SPORE. Investigators funded through the DRP fully participate in SPORE activities, including monthly meetings, allowing an open exchange of ideas and research goals. The SPORE also enhances interactions between DRP researchers and investigators at other SPOREs and institutions. Funded scientists present regular updates on their progress, receiving feedback and any needed problem solving. Over the last four years, projects under the DRP have been reflective of our innovative research programs in lymphoma. Data have contributed toward major specific aims in Projects 1 and 4 of the current SPORE and have generated substantial progress. We are eager to assist a new round of investigators by helping to bring to fruition studies with potential benefit to lymphoma patients and possibly those with other cancers, as well.

发展研究计划（DRP）的目的是确定和支持一流的，开拓性的， 淋巴瘤的翻译项目，尽管他们的潜力，尚未成熟的完整程序状态。所有 希望之城和亚拉巴马伯明翰大学（UAB）的研究团体成员是 鼓励考虑这个机会。我们要求每年提供50，000美元来支持这个项目， City of Hope和UAB每年将分别为这些资金提供10万美元和2.5万美元。至少两 研究人员每年可获得奖金，最多可颁发两年。资金可用于研究 用品和次要设备、人事费和有关会议费用。有希望的调查可能 取代SPORE研究项目，这些项目要么作为独立的R 01/P01项目获得资助，要么作为独立的R 01/P01项目获得资助， 进展并不理想。Larry Kwak博士、Wing（John）Chan博士和Ravi Bhatia博士， 在他们的领域的领导者，是发展计划主任。将公布申请 发给了整个希望之城和UAB研究委员会妇女和少数群体的建议 申请人受到鼓励。根据科学价值、受益的可能性 淋巴瘤患者，关键人员的资格，以及与项目互动的可能性， 希望之城淋巴瘤孢子的核心。选定的项目完全融入整个SPORE。 通过DRP资助的研究者充分参与SPORE活动，包括每月会议， 允许思想和研究目标的开放交流。孢子还增强了 DRP研究人员和其他SPORE和机构的调查人员。受资助的科学家定期 更新他们的进度，接收反馈和任何需要解决的问题。在过去的四年里， DRP下的项目反映了我们在淋巴瘤方面的创新研究计划。数据具有 为当前SPORE项目1和4的主要具体目标做出了贡献，并产生了 实质性进展。我们渴望协助新一轮的调查，帮助实现研究成果 对淋巴瘤患者和其他癌症患者也有潜在的益处。